Literature DB >> 15149739

Molecular mechanisms of prostate cancer.

Kati P Porkka1, Tapio Visakorpi.   

Abstract

During the last ten years our knowledge of genetic alterations in prostate cancer has significantly increased. For example, several chromosomal loci possibly harboring predisposing or somatically mutated genes have been suggested. Still, we lack the comprehensive molecular model for the development and progression of prostate cancer. Only a few genes have been found to be aberrant in a significant proportion of prostate cancer. These include GSTP1, PTEN, TP53, and AR. Thus, they are natural targets for new treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15149739     DOI： 10.1016/j.eururo.2004.01.012

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  17 in total

1.  Androgen receptor CAG and GGC polymorphisms in Mediterraneans: repeat dynamics and population relationships.

Authors:  Esther Esteban; Natalia Rodon; Marc Via; Emili Gonzalez-Perez; Josep Santamaria; Jean-Michel Dugoujon; Farha El Chennawi; Mohamed Melhaoui; Mohamed Cherkaoui; Giuseppe Vona; Nourdin Harich; Pedro Moral
Journal:  J Hum Genet       Date:  2005-12-20       Impact factor: 3.172

2.  Identification of a tumour suppressor network opposing nuclear Akt function.

Authors:  Lloyd C Trotman; Andrea Alimonti; Pier Paolo Scaglioni; Jason A Koutcher; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2006-05-07       Impact factor: 49.962

3.  Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy.

Authors:  Mohammad R Noori-Daloii; Majid Momeny; Mehdi Yousefi; Forough Golsaz Shirazi; Mehdi Yaseri; Nasrin Motamed; Nazanin Kazemialiakbar; Saeed Hashemi
Journal:  Med Oncol       Date:  2010-07-02       Impact factor: 3.064

4.  The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.

Authors:  Shen Gao; Peng Lee; Hua Wang; William Gerald; Michael Adler; Liying Zhang; Yun-Fang Wang; Zhengxin Wang
Journal:  Mol Endocrinol       Date:  2005-02-24

Review 5.  Genomics of prostate cancer: is there anything to "translate"?

Authors:  László Kopper; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

6.  MYC and Prostate Cancer.

Authors:  Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Genes Cancer       Date:  2010-06

Review 7.  Patented prostate cancer biomarkers.

Authors:  Lisa Murphy; R William Watson
Journal:  Nat Rev Urol       Date:  2012-07-03       Impact factor: 14.432

8.  Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β₃ affinity modulation.

Authors:  A Goc; J Liu; T V Byzova; P R Somanath
Journal:  Br J Cancer       Date:  2012-07-05       Impact factor: 7.640

9.  hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer.

Authors:  Renty B Franklin; Pei Feng; B Milon; Mohamed M Desouki; Keshav K Singh; André Kajdacsy-Balla; Omar Bagasra; Leslie C Costello
Journal:  Mol Cancer       Date:  2005-09-09       Impact factor: 27.401

Review 10.  The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Mol Cancer       Date:  2006-05-15       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.